ASX
Paradigm Biopharmaceuticals Limited
PAR:ASX•Healthcare
Sensitive ASX Announcement
Preclinical study underpins efficacy of Paradigm's RhinosulR
Published: 16/09/16, 09:07am (AEST)•2 pages